Worth Watching: Could Cyclacel Pharmaceuticals Inc Crash Even More? The Stock Just Made 52 Week Low

Worth Watching: Could Cyclacel Pharmaceuticals Inc Crash Even More? The Stock Just Made 52 Week Low

The stock of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) hit a new 52-week low and has $2.86 target or 13.00% below today’s $3.29 share price. The 8 months bearish chart indicates high risk for the $11.87 million company. The 1-year low was reported on Nov, 7 by Barchart.com. If the $2.86 price target is reached, the company will be worth $1.54 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 19,889 shares traded hands. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has declined 30.21% since April 5, 2016 and is downtrending. It has underperformed by 32.16% the S&P500.

Analysts await Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) to report earnings on November, 10. They expect $-0.94 earnings per share, up 2.08% or $0.02 from last year’s $-0.96 per share. After $-1.01 actual earnings per share reported by Cyclacel Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -6.93% EPS growth.

According to Zacks Investment Research, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.”

Insitutional Activity: The institutional sentiment decreased to 0.09 in 2016 Q2. Its down 3.58, from 3.67 in 2016Q1. The ratio worsened, as 23 funds sold all Cyclacel Pharmaceuticals Inc shares owned while 0 reduced positions. 2 funds bought stakes while 0 increased positions. They now own 13,631 shares or 99.80% less from 6.70 million shares in 2016Q1.
Tower Rech Capital (Trc) reported 378 shares or 0% of all its holdings. The New York-based Baker Bros Advsr Limited Partnership has invested 0% in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC).

More important recent Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on September 11, 2009, also Investorplace.com published article titled: “Cyclacel Pharmaceuticals Inc (CYCC): Don’t Believe the Hype”, Seekingalpha.com published: “Cyclacel Pharmaceuticals, Inc.’s (CYCC) CEO Spiro Rombotis on Q2 2016 Results …” on August 10, 2016. More interesting news about Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) was released by: Quotes.Wsj.com and their article: “News Cyclacel Pharmaceuticals Inc.CYCC” with publication date: February 11, 2011.

CYCC Company Profile

Cyclacel Pharmaceuticals, Inc., incorporated on January 5, 1996, operates in the field of cell cycle biology. The Firm has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. The Company’s family of anticancer drugs acts on the cell cycle.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment